These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 3097872)

  • 41. Activation of the fibrinolytic system.
    Robison AK; Collen D
    Cardiol Clin; 1987 Feb; 5(1):13-9. PubMed ID: 3103919
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biochemical properties of conjugates of urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin.
    Dewerchin M; Lijnen HR; Van Hoef B; De Cock F; Collen D
    Eur J Biochem; 1989 Oct; 185(1):141-9. PubMed ID: 2530085
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins.
    Toki N; Sumi H; Sasaki K; Boreisha I; Robbins KC
    J Clin Invest; 1985 Apr; 75(4):1212-22. PubMed ID: 3921568
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
    Carr ME; Alving BM
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):567-73. PubMed ID: 7578900
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction.
    Kunitada S; FitzGerald GA; Fitzgerald DJ
    Blood; 1992 Mar; 79(6):1420-7. PubMed ID: 1547340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments.
    Gurewich V; Pannell R
    Blood; 1987 Mar; 69(3):769-72. PubMed ID: 2949785
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB; Moukhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro.
    Ries M; Zenker M; Klinge J; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1995 Aug; 17(3):260-4. PubMed ID: 7620925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
    Keijer J; Linders M; van Zonneveld AJ; Ehrlich HJ; de Boer JP; Pannekoek H
    Blood; 1991 Jul; 78(2):401-9. PubMed ID: 1712649
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of kringles derived from human plasminogen on fibrinolysis in vitro.
    Sugiyama N; Iwamoto M; Abiko Y
    Thromb Res; 1987 Aug; 47(4):459-68. PubMed ID: 2821651
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro fibrinolysis after adding low doses of plasminogen activators and plasmin generation with and without oxidative inactivation of plasmin inhibitors in newborns and adults.
    Ries M; Klinge J; Rauch R; Trusen B; Zenker M; Keuper H; Harms D
    J Pediatr Hematol Oncol; 1996 Nov; 18(4):346-51. PubMed ID: 8888740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct microscopic monitoring of initial and dynamic clot lysis using plasmin or rt-PA in an in vitro flow system.
    Bizjak N; Bajd F; Vidmar J; Blinc A; Perme MP; Marder VJ; Novokhatny V; Serša I
    Thromb Res; 2014 May; 133(5):908-13. PubMed ID: 24613694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
    Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
    Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
    Bookstein JJ; Saldinger E
    Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
    Stump DC; Stassen JM; Demarsin E; Collen D
    Blood; 1987 Feb; 69(2):592-6. PubMed ID: 3099862
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impaired clot lysis by rt-PA catalyzed mini-plasminogen activation.
    Duboscq C; Genoud V; Parborell MF; Kordich LC
    Thromb Res; 1997 Jun; 86(6):505-13. PubMed ID: 9219330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.